Presentations by Event

Presented at ID Week, San Francisco, October 2017

Safety and Pharmacokinetics (PK) in Humans of Intravenous ETX2514, a β–lactamase Inhibitor (BLI) which Broadly Inhibits Ambler Class A, C, and D β–lactamases.

Robin Isaacs

Program(s): etx2514